$AMBS is expecting significant news this week.
Post# of 99122
Posted On: 07/12/2014 1:29:01 PM
$AMBS is expecting significant news this week.
Amarantus Bioscience is currently trading at about a dozen pennies. It's quite possible that this week's news could move it above its all time high of .195.
The company in conjunction with Becton Dickinson will be presenting data this week at the Alzheimer’s Association International Conference being held in Copenhagan, Denmark for its diagnostic blood test, LymPro, to detect early stage Alzheimer's. The commercial launch of the test is scheduled before the end of the year. With all the recent focus on Alzheimer's the test is expected to garner substantial attention from the global media. Unlike other tests to detect Alzheimer's that have been in the news recently LymPro is actually associated with a bio-tech company and headed to market this year.
AMBS also has a patented drug, MANF, which already has three orphan indications. One is for Retinitis Pigmentosa where the company is working with the Bascom Eye Institute. One is in the field of diabetes with the current focus being on MANF as a potential cure for Wolfram's Syndrome.
On July 10 the company's C.E.O., Gerald Commissiong, took the unique approach and held a "Twitter Chat Session" to answer questions from the company's shareholders and other investors. The session lasted for approximately 45 minutes and covered a wide range of topics. For anyone interested in finding out more about the company the following is a link to the chat session:
http://bit.ly/1oQWnZf
No one knows whether or not there is the dark cloud of a market correction looming ahead but for many companies such as AMBS the future looks very bright.
The company has over 10,000 followers on Twitter: @AmarantusBio
Interesting months ahead.
p.s. You'll find out from the chat session that AMBS plans to up-list this year.
Amarantus Bioscience is currently trading at about a dozen pennies. It's quite possible that this week's news could move it above its all time high of .195.
The company in conjunction with Becton Dickinson will be presenting data this week at the Alzheimer’s Association International Conference being held in Copenhagan, Denmark for its diagnostic blood test, LymPro, to detect early stage Alzheimer's. The commercial launch of the test is scheduled before the end of the year. With all the recent focus on Alzheimer's the test is expected to garner substantial attention from the global media. Unlike other tests to detect Alzheimer's that have been in the news recently LymPro is actually associated with a bio-tech company and headed to market this year.
AMBS also has a patented drug, MANF, which already has three orphan indications. One is for Retinitis Pigmentosa where the company is working with the Bascom Eye Institute. One is in the field of diabetes with the current focus being on MANF as a potential cure for Wolfram's Syndrome.
On July 10 the company's C.E.O., Gerald Commissiong, took the unique approach and held a "Twitter Chat Session" to answer questions from the company's shareholders and other investors. The session lasted for approximately 45 minutes and covered a wide range of topics. For anyone interested in finding out more about the company the following is a link to the chat session:
http://bit.ly/1oQWnZf
No one knows whether or not there is the dark cloud of a market correction looming ahead but for many companies such as AMBS the future looks very bright.
The company has over 10,000 followers on Twitter: @AmarantusBio
Interesting months ahead.
p.s. You'll find out from the chat session that AMBS plans to up-list this year.
(0)
(0)